<div id="readability-page-1"><p>Assenagon Asset Management S.A. lessened its position in shares of  AstraZeneca PLC (NASDAQ:AZN - Free Report) by 48.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 598,354 shares of the company's stock after selling 569,162 shares during the period. Assenagon Asset Management S.A.'s holdings in AstraZeneca were worth $45,906,000 as of its most recent filing with the Securities and Exchange Commission.</p><ul><li>How Does D-Wave Stack Up Against Quantum Competitors?</li></ul><p>Several other institutional investors and hedge funds have also bought and sold shares of the company. Primecap Management Co. CA grew its position in shares of  AstraZeneca by 1.3% during the 2nd quarter. Primecap Management Co. CA now owns 41,200,091 shares of the company's stock valued at $2,879,062,000 after purchasing an additional 538,606 shares in the last quarter.  Franklin Resources Inc. raised its position in shares of  AstraZeneca by 0.9% in the second quarter. Franklin Resources Inc. now owns 21,298,394 shares of the company's stock worth $1,488,332,000 after buying an additional 196,401 shares in the last quarter.  Fisher Asset Management LLC boosted its stake in  AstraZeneca by 2.6% during the second quarter. Fisher Asset Management LLC now owns 20,695,979 shares of the company's stock valued at $1,446,235,000 after buying an additional 530,520 shares during the period.  Jennison Associates LLC grew its position in  AstraZeneca by 15.2% during the second quarter. Jennison Associates LLC now owns 12,167,365 shares of the company's stock worth $850,255,000 after buying an additional 1,605,133 shares in the last quarter.  Finally, Ameriprise Financial Inc. grew its position in  AstraZeneca by 2.1% during the second quarter. Ameriprise Financial Inc. now owns 5,046,992 shares of the company's stock worth $351,734,000 after buying an additional 104,625 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Analyst Ratings Changes</h2><p>A number of analysts have recently issued reports on AZN shares. Morgan Stanley  reiterated an &#34;overweight&#34; rating and set a $103.00 price target on shares of AstraZeneca in a research report on Wednesday, December 3rd. Jefferies Financial Group assumed coverage on shares of AstraZeneca in a research note on Monday, October 27th. They issued a &#34;buy&#34; rating on the stock. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Thursday, October 16th. Guggenheim  reissued a &#34;buy&#34; rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Finally, HSBC  restated a &#34;buy&#34; rating and set a $108.00 price objective on shares of AstraZeneca in a research report on Wednesday, December 10th. Eight equities research analysts have rated the stock with a Buy rating and one  has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $95.75.</p><ul><li>Tempus AI Stock: Time to Double Down or Cut and Run?</li></ul><p><b>Get Our Latest Report on AstraZeneca</b></p><h2>AstraZeneca Trading Down 1.6%</h2><p>AZN stock opened at $89.86 on Thursday. The company has a market capitalization of $278.69 billion, a PE ratio of 29.85, a price-to-earnings-growth ratio of 1.69 and a beta of 0.32. AstraZeneca PLC has a one year low of $61.24 and a one year high of $94.01. The company's 50 day moving average price is $87.35 and its two-hundred day moving average price is $79.57. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. </p><ul><li>Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal</li></ul><p>AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.14 by $0.05. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The company had revenue of $15.19 billion during the quarter, compared to analysts' expectations of $14.75 billion. During the same quarter in the prior year, the company earned $2.08 EPS. The firm's revenue was up 12.0% on a year-over-year basis.  As a group, analysts predict that  AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year. </p><h2>AstraZeneca Profile</h2> (Free Report)<p>AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than AstraZeneca</li><li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li><li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li><li>How to Profit From Growth Investing </li><li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li><li>Most active stocks: Dollar volume vs share volume</li><li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li></ul><p><strong>Want to see what other hedge funds are holding AZN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AstraZeneca Right Now?</h2><p>Before you consider AstraZeneca, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.</p><p>While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Assenagon Asset Management S.A. reduced its stake in AstraZeneca PLC by 48.7% in the third quarter, selling 569,162 shares. The firm's holdings are now valued at $45.9 million. Other institutional investors have also adjusted their positions in AstraZeneca. The company reported strong quarterly earnings, with a 12% revenue increase year-over-year. Analysts maintain a 'Moderate Buy' consensus with a price target of $95.75. AstraZeneca's stock opened at $89.86, with a market cap of $278.69 billion.</p>

Assenagon Asset Management S.A. Sells 569,162 Shares of AstraZeneca PLC $AZN